{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:18:00Z","timestamp":1787062680664,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA251063-05"],"award-info":[{"award-number":["T32-CA251063-05"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.lungcan.2026.109356","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:21:14Z","timestamp":1772641274000},"page":"109356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SGLT2 inhibitor use reduces progression and surgical intervention of persistent pulmonary nodules"],"prefix":"10.1016","volume":"215","author":[{"given":"Katherine","family":"Ortmeyer Welch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-8646","authenticated-orcid":false,"given":"Kelly A.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Krouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109356_b0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jama.2021.24287","article-title":"Evaluating the patient with a pulmonary nodule: a review","volume":"327","author":"Mazzone","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109356_b0010","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhou L, Yang F, Li X. The natural growth history of persistent pulmonary subsolid nodules: Radiology, genetics, and clinical management. Front Oncol. 2022;1Accessed February 12, 2024. https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2022.1011712.","DOI":"10.3389\/fonc.2022.1011712"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109356_b0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1148\/radiol.2017162894","article-title":"Recommendations for measuring pulmonary nodules at CT: a statement from the Fleischner society","volume":"285","author":"Bankier","year":"2017","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109356_b0020","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1878-0261.13508","article-title":"Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1\u03b1","volume":"17","author":"Biziotis","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.lungcan.2026.109356_b0025","doi-asserted-by":"crossref","unstructured":"Scafoglio CR, Villegas B, Abdelhady G, et al. Sodium-Glucose Transporter 2 is a diagnostic and therapeutic target for early stage lung adenocarcinoma. Sci Transl Med. 2018;10(467):eaat5933. doi:10.1126\/scitranslmed.aat5933.","DOI":"10.1126\/scitranslmed.aat5933"},{"issue":"30","key":"10.1016\/j.lungcan.2026.109356_b0030","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lungcan.2026.109356_b0035","doi-asserted-by":"crossref","unstructured":"Ding L, Chen X, Zhang W, et al. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest. 133(1):e154754. doi:10.1172\/JCI154754.","DOI":"10.1172\/JCI154754"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109356_b0040","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109356_b0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2017161659","article-title":"Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner society 2017","volume":"284","author":"MacMahon","year":"2017","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109356_b0050","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11154-021-09675-9","article-title":"Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment \u2013 a Review","volume":"22","author":"Lau","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109356_b0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/biomedicines11071867","article-title":"SGLT2 inhibitors as potential anticancer agents","volume":"11","author":"Basak","year":"2023","journal-title":"Biomedicines"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109356_b0060","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment\u2014mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109356_b0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40170-023-00306-2","article-title":"Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study","volume":"11","author":"Park","year":"2023","journal-title":"Cancer Metab."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109356_b0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5414\/CP204465","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population","volume":"61","author":"Tanaka","year":"2023","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109356_b0075","article-title":"The effect of SGLT2 inhibition on prostate cancer: mendelian randomization and observational analysis using electronic healthcare and cohort data","volume":"5","author":"Zheng","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109356_b0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109356_b0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109356_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109356_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109356_b0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","article-title":"SGLT gene expression in primary lung cancers and their metastatic lesions","volume":"92","author":"Ishikawa","year":"2001","journal-title":"Jpn J. Cancer Res. Gann."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109356_b0105","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109356_b0110","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/biom10060868","article-title":"Heterogeneity of Glucose Transport in Lung Cancer","volume":"10","author":"Martinez","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109356_b0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-022-02496-z","article-title":"SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways","volume":"22","author":"Wang","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109356_b0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13340-021-00494-6","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro","volume":"12","author":"Yamamoto","year":"2021","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.lungcan.2026.109356_b0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2017.00288","article-title":"Identification of clinically approved drugs indacaterol and canagliflozin for repurposing to treat epidermal growth factor tyrosine kinase inhibitor-resistant lung cancer","volume":"7","author":"Li","year":"2017","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109356_b0130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metab."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109356_b0135","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109356_b0140","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109356_b0145","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1164\/rccm.201505-0990OC","article-title":"Recent trends in the identification of incidental pulmonary nodules","volume":"192","author":"Gould","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109356_b0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.chest.2023.06.009","article-title":"The thoracic research evaluation and treatment 2.0 model: a lung cancer prediction model for indeterminate nodules referred for specialist evaluation","volume":"164","author":"Godfrey","year":"2023","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109356_b0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.rcl.2018.01.002","article-title":"Management of Incidental Lung Nodules: current strategy and Rationale","volume":"56","author":"Alpert","year":"2018","journal-title":"Radiol. Clin. North Am."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109356_b0160","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00330-022-09138-y","article-title":"The long-term course of subsolid nodules and predictors of interval growth on chest CT: a systematic review and meta-analysis","volume":"33","author":"Wu","year":"2023","journal-title":"Eur. Radiol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109356_b0165","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2016.04.006","article-title":"Natural history of pulmonary subsolid nodules: a prospective multicenter study","volume":"11","author":"Kakinuma","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.lungcan.2026.109356_b0170","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.21037\/tlcr.2019.10.24","article-title":"Optimal management of pulmonary ground-glass opacity nodules","volume":"8","author":"Kim","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109356_b0175","first-page":"354","article-title":"Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?","volume":"2","author":"Kobayashi","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109356_b0180","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cllc.2023.09.003","article-title":"Outcome of incidental pulmonary nodules in a real-world setting","volume":"24","author":"Vindum","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109356_b0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lungcan.2026.109356_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107759","article-title":"Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator","volume":"216","author":"Sardu","year":"2025","journal-title":"Pharmacol. Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:26:06Z","timestamp":1775622366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S0169500226004174"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109356","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor use reduces progression and surgical intervention of persistent pulmonary nodules","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109356"}}